Currently Viewing:
Newsroom
Currently Reading
Following Pembrolizumab, Nivolumab Trials in Multiple Myeloma Paused
September 07, 2017 – Surabhi Dangi-Garimella, PhD
Companies Continue to Face Challenges With Developing CAR-T Treatment
September 05, 2017 – Surabhi Dangi-Garimella, PhD
Mammography Device Approved by FDA Gives Patients Control Over Pressure Levels
September 05, 2017 – Christina Mattina
Consistent Use of E-Cigarettes Can Help Smoking Cessation
September 04, 2017 – AJMC Staff
Healthy, but Still Hurting: Challenges of Cancer Survivorship
September 04, 2017 – Laura Joszt
Severe Psoriasis Linked to Increased Risk of Death
September 02, 2017 – Laura Joszt
Patient Support Program Improves Adherence to TNF Inhibitors in RA and IBD
September 02, 2017 – Laura Joszt
A New Treatment Option for Newly Diagnosed AML: Gemtuzumab Ozogamicin
September 01, 2017 – AJMC Staff
5 Significant Developments With CAR-T Therapy
September 01, 2017 – Surabhi Dangi-Garimella, PhD

Following Pembrolizumab, Nivolumab Trials in Multiple Myeloma Paused

Surabhi Dangi-Garimella, PhD
Bristol-Myers Squibb announced that the FDA has placed a clinical hold on 3 combination trials evaluating its programmed death-1 inhibitor nivolumab (Opdivo) in patients with relapsed/refractory multiple myeloma.
In a press release late Wednesday, Bristol-Myers Squibb (BMS) announced that the FDA has placed a clinical hold on 3 combination trials evaluating its programmed death-1 (PD-1) inhibitor nivolumab (Opdivo) in patients with relapsed/refractory multiple myeloma.

The hold, according to the company, is in reaction to trials evaluating another anti–PD-1 agent, pembrolizumab (Keytruda), that were placed on hold following patient deaths. In July, Merck, which has developed pembrolizumab, announced that the FDA’s decision applied to KEYNOTE-183, KEYNOTE-185, and KEYNOTE-023; the trials were evaluating the drug in combination with various other agents in either treatment-naïve or relapsed/refractory patients with multiple myeloma.

Earlier this week, the FDA followed up with a more detailed analysis of what resulted in the deaths—higher rate of grade 3 to 5 toxicities, higher rate of serious adverse events, and some non-cancer causes of death, including cardiac events and intestinal ischemia.

Nivolumab trials that have been placed on partial clinical hold include:
  • CheckMate-602: A phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
  • CheckMate-039: A phase 1 study to establish the tolerability of nivolumab and the combination of nivolumab and daratumumab, with or without IMiD (pomalidomide and dexamethasone), in subjects with relapsed or refractory multiple myeloma
  • CA204142: A phase 2 study of elotuzumab in combination with pomalidomide and low-dose dexamethasone, and in combination with nivolumab, in patients with multiple myeloma relapsed or refractory to prior treatment with lenalidomide
Other nivolumab studies for indications other than multiple myeloma will continue as planned, according to the BMS release.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up